GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS
First Claim
Patent Images
1. A peptide comprising the amino acid sequence of:
- a) SEQ ID NO;
12;
b) SEQ ID NO;
13;
c) SEQ ID NO;
14;
d) SEQ ID NO;
15, ore) SEQ ID NO;
16;
or a pharmaceutically acceptable salt thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
-
Citations
21 Claims
-
1. A peptide comprising the amino acid sequence of:
-
a) SEQ ID NO;
12;b) SEQ ID NO;
13;c) SEQ ID NO;
14;d) SEQ ID NO;
15, ore) SEQ ID NO;
16;or a pharmaceutically acceptable salt thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
9. A conjugate comprising a peptide of claim 1 conjugated to a heterologous moiety, or a pharmaceutically acceptable salt thereof, wherein the conjugate exhibits enhanced activity at the GLP-1 receptor, as compared to native glucagon, and exhibits at least 100-fold greater selectivity for the human GLP-1 receptor versus the GIP receptor.
-
10. The conjugate of claim 9, wherein the heterologous moiety comprises one or more of:
- a peptide, a polypeptide, a nucleic acid molecule, an antibody or fragment thereof, a polymer, a quantum dot, a small molecule, a toxin, a diagonostic agent, or a pharmaceutically acceptable salt thereof.
-
11. The conjugate of claim 10, comprising an extension of 1-21 amino acids C-terminal to the amino acid at position 31 of the peptide or variant peptide, or a pharmaceutically acceptable salt thereof.
-
12. The conjugate of claim 11, wherein the extension is selected from the group consisting of:
- Gly, Glu, Cys, Gly-Gly, Gly-Glu, GPSSGAPPPS (SEQ ID NO;
9) or GGPSSGAPPPS (SEQ ID NO;
10), or a pharmaceutically acceptable salt thereof.
- Gly, Glu, Cys, Gly-Gly, Gly-Glu, GPSSGAPPPS (SEQ ID NO;
-
13. A dimer or multimer comprising a peptide of claim 1, or a pharmaceutically acceptable salt thereof.
-
14. A pharmaceutical composition comprising the peptide of claim 1, or a pharmaceutically acceptable salt thereof.
-
15. The pharmaceutical composition of claim 14, comprising an anti-diabetic or anti-obesity agent.
-
16. A method of treating a disease or medical condition in a patient, wherein the disease or medical condition is selected from the group consisting of:
- metabolic syndrome, diabetes, obesity, liver steatosis, and a neurodegenerative disease, comprising administering to the patient the pharmaceutical composition of claim 14 in an amount effective to treat the disease or medical condition.
-
17. A conjugate comprising a variant peptide of claim 3 conjugated to a heterologous moiety, or a pharmaceutically acceptable salt thereof, wherein the conjugate exhibits enhanced activity at the GLP-1 receptor, as compared to native glucagon, and exhibits at least 100-fold greater selectivity for the human GLP-1 receptor versus the GIP receptor.
-
18. The conjugate of claim 17, wherein the heterologous moiety comprises one or more of:
- a peptide, a polypeptide, a nucleic acid molecule, an antibody or fragment thereof, a polymer, a quantum dot, a small molecule, a toxin, a diagonostic agent, or a pharmaceutically acceptable salt thereof.
-
19. The conjugate of claim 18, comprising an extension of 1-21 amino acids C-terminal to the amino acid at position 31 of the peptide or variant peptide, or a pharmaceutically acceptable salt thereof.
-
20. The conjugate of claim 19, wherein the extension is selected from the group consisting of:
- Gly, Glu, Cys, Gly-Gly, Gly-Glu, GPSSGAPPPS (SEQ ID NO;
9) or GGPSSGAPPPS (SEQ ID NO;
10), or a pharmaceutically acceptable salt thereof.
- Gly, Glu, Cys, Gly-Gly, Gly-Glu, GPSSGAPPPS (SEQ ID NO;
-
21. A pharmaceutical composition comprising the variant peptide of claim 3, or a pharmaceutically acceptable salt thereof.
-
Specification